Skip to main content
. 2014 Oct 22;41(1):39–45. doi: 10.1111/apt.12993

Figure 2.

Figure 2

Time to first breakthrough HE event during placebo treatment in the RCT and during rifaximin treatment in OLM study. Open circles and open triangles represent censored data. *Event rate was calculated for 168 days of the RCT and the first 168 days in the OLM study. HE, hepatic encephalopathy; OLM, open-label maintenance; RCT, randomised, controlled trial.